Sujet(s)
Calcium-Transporting ATPases , Mutation , Infections à papillomavirus , Pemphigus chronique bénin familial , Humains , Pemphigus chronique bénin familial/génétique , Pemphigus chronique bénin familial/anatomopathologie , Infections à papillomavirus/génétique , Calcium-Transporting ATPases/génétique , Mâle , Femelle , Adulte d'âge moyen , Virus des Papillomavirus humains , AlphapapillomavirusRÉSUMÉ
ABSTRACT Background: The association of prostate cancer antigen 3 (PCA3) polymorphism (SNP, rs544190G>A) with metastatic prostate cancer in European descent has been reported. Our aim of the current study was to re-validate the effect of PCA3 polymorphism on prostate cancer risk in an Eastern Chinese population and then estimate possible genetic discrepancies among population. Materials and Methods: Taqman assay was employed to determine genotype of SNP rs544190 in 1015 ethnic Han Chinese patients with prostate cancer and 1032 cancer-free controls. Simultaneously, odds ratios (OR) and 95% confidence intervals (95%CI) for risk relationship were calculated by logistic regression models. Results: The statistically significant relationship between PCA3 rs544190G>A and higher prostate cancer risk was not found. Stratification analysis revealed that there was no remarkable association of rs544190 variant AG/AA genotype with prostate cancer risk in every subgroup, except for patients with Gleason score ≤7(3+4). Conclusion: Although the results demonstrated that SNP rs544190 was not involved in prostate cancer risk in Eastern Chinese descent, unlike in European population, these might have clinical implications on prostate cancer heterogeneity around the World. To validate these findings, well-designed studies with different ethnic populations are warranted.
Sujet(s)
Humains , Mâle , Sujet âgé , Tumeurs de la prostate/génétique , Appréciation des risques/méthodes , Polymorphisme de nucléotide simple/génétique , Asiatiques/génétique , Antigènes néoplasiques/génétique , Tumeurs de la prostate/ethnologie , Tumeurs de la prostate/anatomopathologie , Fumer/effets indésirables , Études cas-témoins , Expression des gènes , Modèles logistiques , Chine , Facteurs de risque , Études d'associations génétiques , Grading des tumeurs , Génotype , Stadification tumoraleRÉSUMÉ
BACKGROUND: The association of prostate cancer antigen 3 (PCA3) polymorphism (SNP, rs544190G>A) with metastatic prostate cancer in European descent has been reported. Our aim of the current study was to re-validate the effect of PCA3 polymorphism on prostate cancer risk in an Eastern Chinese population and then estimate possible genetic discrepancies among population. MATERIALS AND METHODS: Taqman assay was employed to determine genotype of SNP rs544190 in 1015 ethnic Han Chinese patients with prostate cancer and 1032 cancerfree controls. Simultaneously, odds ratios (OR) and 95% confidence intervals (95%CI) for risk relationship were calculated by logistic regression models. RESULTS: The statistically significant relationship between PCA3 rs544190G>A and higher prostate cancer risk was not found. Stratification analysis revealed that there was no remarkable association of rs544190 variant AG/AA genotype with prostate cancer risk in every subgroup, except for patients with Gleason score ≤7(3+4). CONCLUSION: Although the results demonstrated that SNP rs544190 was not involved in prostate cancer risk in Eastern Chinese descent, unlike in European population, these might have clinical implications on prostate cancer heterogeneity around the World. To validate these findings, well-designed studies with different ethnic populations are warranted.
Sujet(s)
Antigènes néoplasiques/génétique , Asiatiques/génétique , Polymorphisme de nucléotide simple/génétique , Tumeurs de la prostate/génétique , Appréciation des risques/méthodes , Sujet âgé , Études cas-témoins , Chine , Expression des gènes , Études d'associations génétiques , Génotype , Humains , Modèles logistiques , Mâle , Grading des tumeurs , Stadification tumorale , Tumeurs de la prostate/ethnologie , Tumeurs de la prostate/anatomopathologie , Facteurs de risque , Fumer/effets indésirablesRÉSUMÉ
PURPOSES: To examine the factors related to the choice of cytoreductive nephrectomy (CN) for patients with metastatic clear cell renal cell carcinoma (mCCRCC), and compare the population-based survival rates of patients treated with or without surgery in the modern targeted therapy era. MATERIALS AND METHODS: From 2006 to 2009, patients with mCCRCC were identified from SEER database. The factors that affected patients to be submitted to CN were examined and propensity scores for each patient were calculated. Then patients were matched based upon propensity scores. Univariable and multivariable cox regression models were used to compare survival rates of patients treated with or without surgery. Finally, sensitivity analysis for the cox model on a hazard ratio scale was performed. RESULTS: Age, race, tumor size, T stage and N stage were associated with nephrectomy univariablely. After the match based upon propensity scores, the 1-, 2-, and 3-year cancer-specific survival rate estimates were 45.1%, 27.9%, and 21.7% for the no-surgery group vs 70.6%, 52.2%, and 41.7% for the surgery group, respectively (hazard ratio 0.42, 95%CI: 0.35-0.52, log-rank P<0.001). In multivariable Cox proportional hazard regression model, race, T stage, N stage and median household income were significantly associated with survival. Sensitivity analysis on a hazard ratio scale indicated that the hazard ratio might be above 1.00 only when the unknown factor had an opposite effect on survival which was 3-fold than CN. CONCLUSION: The results of our study showed that CN significantly improves the survival of patients with metastatic CCRCC even in the targeted therapy era.
Sujet(s)
Néphrocarcinome/mortalité , Néphrocarcinome/chirurgie , Interventions chirurgicales de cytoréduction/méthodes , Tumeurs du rein/mortalité , Tumeurs du rein/chirurgie , Néphrectomie/méthodes , Facteurs âges , Sujet âgé , Néphrocarcinome/anatomopathologie , Néphrocarcinome/secondaire , Femelle , Humains , Tumeurs du rein/anatomopathologie , Tumeurs du rein/secondaire , Mâle , Adulte d'âge moyen , Stadification tumorale , Score de propension , Modèles des risques proportionnels , Programme SEER , Facteurs sexuels , Facteurs socioéconomiques , Facteurs temps , Résultat thérapeutique , Charge tumoraleRÉSUMÉ
Purposes To examine the factors related to the choice of cytoreductive nephrectomy (CN) for patients with metastatic clear cell renal cell carcinoma (mCCRCC), and compare the population-based survival rates of patients treated with or without surgery in the modern targeted therapy era. Materials and Methods From 2006 to 2009, patients with mCCRCC were identified from SEER database. The factors that affected patients to be submitted to CN were examined and propensity scores for each patient were calculated. Then patients were matched based upon propensity scores. Univariable and multivariable cox regression models were used to compare survival rates of patients treated with or without surgery. Finally, sensitivity analysis for the cox model on a hazard ratio scale was performed. Results Age, race, tumor size, T stage and N stage were associated with nephrectomy univariablely. After the match based upon propensity scores, the 1-, 2-, and 3-year cancer-specific survival rate estimates were 45.1%, 27.9%, and 21.7% for the no-surgery group vs 70.6%, 52.2%, and 41.7% for the surgery group, respectively (hazard ratio 0.42, 95%CI: 0.35-0.52, log-rank P<0.001). In multivariable Cox proportional hazard regression model, race, T stage, N stage and median household income were significantly associated with survival. Sensitivity analysis on a hazard ratio scale indicated that the hazard ratio might be above 1.00 only when the unknown factor had an opposite effect on survival which was 3-fold than CN. Conclusion The results of our study showed that CN significantly improves the survival of patients with metastatic CCRCC even in the targeted therapy era. .